Alison M. Pack
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Alison M. Pack has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Martha J. Morrell
Department of Neurology, Stanford University
5 shared publicationsElizabeth Shane
Department of Medicine, Columbia University
3 shared publicationsEdith Flaster
Department of Neurology, Columbia University, New York, NY
2 shared publicationsA. Randall
From the Departments of Neurology (A.M.P., A.R.) and Medicine (D.J.M., E.S.), Columbia University, New York, NY; and Department of Neurology (M.J.M.), Stanford University, Stanford, CA
1 shared publicationAlison Randall
Department of Neurology, Columbia University, New York, NY
1 shared publication- Amanda Dennis
Ibis Reproductive Health, Cambridge, Massachusetts
1 shared publication
Latest Publications
- 1 August 2011
- Published by Elsevier in Epilepsy & Behavior
- Vol. 21 (4) , 453-458
Normal vitamin D and low free estradiol levels in women on enzyme-inducing antiepileptic drugs
- 1 August 2011
- Published by Elsevier in Epilepsy & Behavior
- Vol. 21 (4) , 453-458
Normal vitamin D and low free estradiol levels in women on enzyme-inducing antiepileptic drugs
- 11 May 2011
- Published by Springer Nature in Current Treatment Options in Neurology
- Vol. 13 (4) , 346-354
Treatment of Epilepsy to Optimize Bone Health
When treating a person with epilepsy, one must consider many factors in addition to the obvious need to treat the seizures. Both epilepsy itself and treatment with antiepileptic drugs (AEDs) subject one to numerous potential secondary long-term health concerns. Poor bone health is one of these concerns. Studies suggest that persons with epilepsy treated with AEDs have an increased risk of fracture, low bone mineral density (BMD), and abnormalities in bone metabolism. Multiple factors likely contribute to the increased risk. Falls during generalized tonic-clonic seizures, secondary effects of AEDs on balance, inactivity, low BMD, reduced calcium intake, reduced active vitamin D metabolites, and a genetic predisposition to low BMD may all contribute. Studies suggest a differential influence of AEDs. Phenytoin, phenobarbital, and primidone are most consistently associated with a negative impact on bone. Carbamazepine and valproate may also result in bone abnormalities, but data are mixed. Current studies suggest that lamotrigine has limited (if any) effect, but again, data are inconsistent. Other AEDs have received limited study. Screening for poor bone health includes serologic testing of vitamin D metabolites (notably 25-hydroxyvitamin D) as well as BMD testing using dual energy x-ray absorptiometry. Optimizing intake of calcium and vitamin D is important for all persons with epilepsy treated with AEDs. Although many treatments for low BMD are available, these agents have not been studied in persons with epilepsy treated with AEDs. Overall, physicians treating persons with epilepsy must consider the potential effect of having epilepsy and its main treatment, AED therapy, on bone health. For patients in whom bone health is a particular concern (eg, those with diagnosed bone disease or with significant risk factors for bone disease, including glucocorticosteroid use), it is best to avoid AEDs known to negatively affect bone. In addition, practitioners should work with other treating physicians to optimize bone health in these patients.
- 11 May 2011
- Published by Springer Nature in Current Treatment Options in Neurology
- Vol. 13 (4) , 346-354
Treatment of Epilepsy to Optimize Bone Health
When treating a person with epilepsy, one must consider many factors in addition to the obvious need to treat the seizures. Both epilepsy itself and treatment with antiepileptic drugs (AEDs) subject one to numerous potential secondary long-term health concerns. Poor bone health is one of these concerns. Studies suggest that persons with epilepsy treated with AEDs have an increased risk of fracture, low bone mineral density (BMD), and abnormalities in bone metabolism. Multiple factors likely contribute to the increased risk. Falls during generalized tonic-clonic seizures, secondary effects of AEDs on balance, inactivity, low BMD, reduced calcium intake, reduced active vitamin D metabolites, and a genetic predisposition to low BMD may all contribute. Studies suggest a differential influence of AEDs. Phenytoin, phenobarbital, and primidone are most consistently associated with a negative impact on bone. Carbamazepine and valproate may also result in bone abnormalities, but data are mixed. Current studies suggest that lamotrigine has limited (if any) effect, but again, data are inconsistent. Other AEDs have received limited study. Screening for poor bone health includes serologic testing of vitamin D metabolites (notably 25-hydroxyvitamin D) as well as BMD testing using dual energy x-ray absorptiometry. Optimizing intake of calcium and vitamin D is important for all persons with epilepsy treated with AEDs. Although many treatments for low BMD are available, these agents have not been studied in persons with epilepsy treated with AEDs. Overall, physicians treating persons with epilepsy must consider the potential effect of having epilepsy and its main treatment, AED therapy, on bone health. For patients in whom bone health is a particular concern (eg, those with diagnosed bone disease or with significant risk factors for bone disease, including glucocorticosteroid use), it is best to avoid AEDs known to negatively affect bone. In addition, practitioners should work with other treating physicians to optimize bone health in these patients.
Implications of hormonal and neuroendocrine changes associated with seizures and antiepileptic drugs: A clinical perspective
Epilepsy and antiepileptic drugs (AEDs) affect hormones and neuroendocrine systems, which may result in a change in the seizure threshold (catamenial epilepsy) or in comorbidities including sexual dysfunction, reproductive dysfunction, and abnormalities in bone health. Catamenial epilepsy occurs commonly in women with epilepsy. The most commonly reported and studied mechanism proposed to explain why some women have a catamenial seizure exacerbation relates to cyclic changes in reproductive steroid hormones. Women and men with epilepsy have a higher than expected prevalence of sexual dysfunction. The epilepsy syndrome and localization influence the presentation of sexual dysfunction. Reproductive dysfunction occurs in both men and women with epilepsy. As with sexual dysfunction both the epilepsy syndrome and specific AEDs influence the presentation of reproductive dysfunction. Persons with epilepsy have an increased risk of fracture secondary to decreased bone mineral density (BMD), altered bone quality, and a propensity to fall because of either seizures or side effects of medication. Some AEDs are associated with abnormalities in BMD and bone and mineral metabolism.
Implications of hormonal and neuroendocrine changes associated with seizures and antiepileptic drugs: A clinical perspective
Epilepsy and antiepileptic drugs (AEDs) affect hormones and neuroendocrine systems, which may result in a change in the seizure threshold (catamenial epilepsy) or in comorbidities including sexual dysfunction, reproductive dysfunction, and abnormalities in bone health. Catamenial epilepsy occurs commonly in women with epilepsy. The most commonly reported and studied mechanism proposed to explain why some women have a catamenial seizure exacerbation relates to cyclic changes in reproductive steroid hormones. Women and men with epilepsy have a higher than expected prevalence of sexual dysfunction. The epilepsy syndrome and localization influence the presentation of sexual dysfunction. Reproductive dysfunction occurs in both men and women with epilepsy. As with sexual dysfunction both the epilepsy syndrome and specific AEDs influence the presentation of reproductive dysfunction. Persons with epilepsy have an increased risk of fracture secondary to decreased bone mineral density (BMD), altered bone quality, and a propensity to fall because of either seizures or side effects of medication. Some AEDs are associated with abnormalities in BMD and bone and mineral metabolism.
- 1 July 2008
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 8 (4) , 325-332
Pregnancy registries: What do they mean to clinical practice?
Multiple surveillance pregnancy registries have been established in order to better understand the effects of antiepileptic drugs (AEDs) on pregnancy. These registries are either hospital based, population based, or pharmaceutical based and are primarily focused on the potential teratogenicity of AEDs. The main outcome variable for most of these registries is the risk of major congenital malformations. Registries also gather data on other aspects of pregnancy, including seizure control. The methodology of the registries varies. They have different populations, ascertainment strategies, follow-up, and reporting criteria. These differences limit the ability to allow direct comparisons. Overall, the registry data suggest that the overwhelming majority of women with epilepsy treated with AEDs will have normal, healthy babies. A second consistent finding is that valproate, particularly at higher doses, is associated with a higher risk of major congenital malformations than other AEDs.
- 1 July 2008
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 8 (4) , 325-332
Pregnancy registries: What do they mean to clinical practice?
Multiple surveillance pregnancy registries have been established in order to better understand the effects of antiepileptic drugs (AEDs) on pregnancy. These registries are either hospital based, population based, or pharmaceutical based and are primarily focused on the potential teratogenicity of AEDs. The main outcome variable for most of these registries is the risk of major congenital malformations. Registries also gather data on other aspects of pregnancy, including seizure control. The methodology of the registries varies. They have different populations, ascertainment strategies, follow-up, and reporting criteria. These differences limit the ability to allow direct comparisons. Overall, the registry data suggest that the overwhelming majority of women with epilepsy treated with AEDs will have normal, healthy babies. A second consistent finding is that valproate, particularly at higher doses, is associated with a higher risk of major congenital malformations than other AEDs.
- 3 June 2008
- Published by Springer Nature in Nature Clinical Practice Neurology
- Vol. 4 (7) , 354-355
Should patients with epilepsy be routinely screened for low bone mineral density?
- 3 June 2008
- Published by Springer Nature in Nature Clinical Practice Neurology
- Vol. 4 (7) , 354-355
Should patients with epilepsy be routinely screened for low bone mineral density?
- 29 April 2008
- Published by Wolters Kluwer Health in Neurology
- Vol. 70 (18) , 1586-1593
Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy
Objective: Antiepileptic drugs (AEDs) may have adverse effects on bone mineral density (BMD) and metabolism. We previously reported biochemical evidence of increased bone turnover in premenopausal women with epilepsy on phenytoin monotherapy compared with those on carbamazepine, lamotrigine, and valproate. We therefore hypothesized that rates of bone loss would be higher in young women treated with phenytoin. Methods: Ninety-three premenopausal women with epilepsy receiving a single AED (carbamazepine, lamotrigine, phenytoin, or valproate) participated. Subjects completed nutritional and physical activity questionnaires. Biochemical indices of bone and mineral metabolism and BMD of the proximal femur and lumbar spine were measured at baseline and 1 year. Results: Participants reported high calcium intake (>1,000 mg/day) and were physically active. Significant loss (2.6%) was seen at the femoral neck in the phenytoin group. BMD remained stable in the other AED groups. Bone turnover markers and calciotropic hormones were unchanged after 1 year in all groups except for a significant decline in urine N-telopeptide in the phenytoin group. In women receiving phenytoin, lower serum 25-hydroxyvitamin D concentrations were associated with higher parathyroid hormone, bone alkaline phosphatase, and urine N-telopeptide levels, a biochemical pattern consistent with secondary hyperparathyroidism and increased remodeling. Conclusion: In this study, young women treated with phenytoin had significant femoral neck bone loss over 1 year. In contrast, those treated with carbamazepine, lamotrigine, and valproate did not have detectable adverse effects on bone turnover or bone mineral density. These results raise concerns about the long-term effects of phenytoin monotherapy on bone in young women with epilepsy. GLOSSARY: 1,25(OH)2D = 1,25-dihydroxyvitamin D; AED = antiepileptic drug; ANOVA = analysis of variance; BCE = bone collagen equivalent; BMD = bone mineral density; BMI = body mass index; BSAP = bone-specific alkaline phosphatase; CBZ = carbamazepine; FN = femoral neck; LS = lumbar spine; LTG = lamotrigine; NTx = cross-linked N-telopeptide of type I bone collagen; OHD = 25-hydroxyvitamin D; PHT = phenytoin; PTH = parathyroid hormone; TH = total hip; VPA = valproate.
- 29 April 2008
- Published by Wolters Kluwer Health in Neurology
- Vol. 70 (18) , 1586-1593
Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy
Objective: Antiepileptic drugs (AEDs) may have adverse effects on bone mineral density (BMD) and metabolism. We previously reported biochemical evidence of increased bone turnover in premenopausal women with epilepsy on phenytoin monotherapy compared with those on carbamazepine, lamotrigine, and valproate. We therefore hypothesized that rates of bone loss would be higher in young women treated with phenytoin. Methods: Ninety-three premenopausal women with epilepsy receiving a single AED (carbamazepine, lamotrigine, phenytoin, or valproate) participated. Subjects completed nutritional and physical activity questionnaires. Biochemical indices of bone and mineral metabolism and BMD of the proximal femur and lumbar spine were measured at baseline and 1 year. Results: Participants reported high calcium intake (>1,000 mg/day) and were physically active. Significant loss (2.6%) was seen at the femoral neck in the phenytoin group. BMD remained stable in the other AED groups. Bone turnover markers and calciotropic hormones were unchanged after 1 year in all groups except for a significant decline in urine N-telopeptide in the phenytoin group. In women receiving phenytoin, lower serum 25-hydroxyvitamin D concentrations were associated with higher parathyroid hormone, bone alkaline phosphatase, and urine N-telopeptide levels, a biochemical pattern consistent with secondary hyperparathyroidism and increased remodeling. Conclusion: In this study, young women treated with phenytoin had significant femoral neck bone loss over 1 year. In contrast, those treated with carbamazepine, lamotrigine, and valproate did not have detectable adverse effects on bone turnover or bone mineral density. These results raise concerns about the long-term effects of phenytoin monotherapy on bone in young women with epilepsy. GLOSSARY: 1,25(OH)2D = 1,25-dihydroxyvitamin D; AED = antiepileptic drug; ANOVA = analysis of variance; BCE = bone collagen equivalent; BMD = bone mineral density; BMI = body mass index; BSAP = bone-specific alkaline phosphatase; CBZ = carbamazepine; FN = femoral neck; LS = lumbar spine; LTG = lamotrigine; NTx = cross-linked N-telopeptide of type I bone collagen; OHD = 25-hydroxyvitamin D; PHT = phenytoin; PTH = parathyroid hormone; TH = total hip; VPA = valproate.
- 1 March 2008
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 17 (2) , 181-186
Bone health in people with epilepsy: Is it impaired and what are the risk factors?
- 1 March 2008
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 17 (2) , 181-186
Bone health in people with epilepsy: Is it impaired and what are the risk factors?
- 1 April 2006
- Published by Springer Nature in Nature Clinical Practice Neurology
- Vol. 2 (4) , 190-200
Therapy Insight: clinical management of pregnant women with epilepsy
In pregnant women with epilepsy who are being treated with antiepileptic drugs (AEDs), careful clinical management is vital because seizure frequency can change during pregnancy, and both seizure activity and AED treatment can have consequences for the developing fetus. Complications of epilepsy and AED treatment include stillbirths, prematurity, low birth weight, major and minor malformations, and cognitive delay later in life. Certain AEDs probably have more adverse effects than others; data from prospective studies indicate that phenobarbital and valproate are associated with significant increases in major malformations, and retrospective studies show lower verbal IQs and greater need for extra assistance in school for children whose mothers received valproate during pregnancy. Monitoring of AED levels and dosage adjustment are warranted throughout pregnancy, and vitamin K1 at a dose of 10 mg/day should be given in the last month, particularly when cytochrome P450 enzyme-inducing AEDs are being administered. In the postpartum period, breastfeeding is recommended; however, there is differential transfer of individual AEDs in breast milk, and the infant should be observed clinically. For all women of reproductive age, preconceptual counseling is important, and includes optimization of the AED regimen and advising the mother to take supplemental folic acid.
- 1 April 2006
- Published by Springer Nature in Nature Clinical Practice Neurology
- Vol. 2 (4) , 190-200
Therapy Insight: clinical management of pregnant women with epilepsy
In pregnant women with epilepsy who are being treated with antiepileptic drugs (AEDs), careful clinical management is vital because seizure frequency can change during pregnancy, and both seizure activity and AED treatment can have consequences for the developing fetus. Complications of epilepsy and AED treatment include stillbirths, prematurity, low birth weight, major and minor malformations, and cognitive delay later in life. Certain AEDs probably have more adverse effects than others; data from prospective studies indicate that phenobarbital and valproate are associated with significant increases in major malformations, and retrospective studies show lower verbal IQs and greater need for extra assistance in school for children whose mothers received valproate during pregnancy. Monitoring of AED levels and dosage adjustment are warranted throughout pregnancy, and vitamin K1 at a dose of 10 mg/day should be given in the last month, particularly when cytochrome P450 enzyme-inducing AEDs are being administered. In the postpartum period, breastfeeding is recommended; however, there is differential transfer of individual AEDs in breast milk, and the infant should be observed clinically. For all women of reproductive age, preconceptual counseling is important, and includes optimization of the AED regimen and advising the mother to take supplemental folic acid.
- 1 July 2005
- Published by Springer Nature in Current Treatment Options in Neurology
- Vol. 7 (4) , 273-280
Effects of treatment on endocrine function in patients with epilepsy
Antiepileptic drug (AED) treatment is associated with multiple short- and long-term side effects. Effects on endocrine function, including weight change, reproductive function, thyroid function, and bone health are examples of these side effects. Some AEDs affect weight, resulting in weight gain or loss. Levetiracetam and lamotrigine are weight-neu-tral agents, whereas valproate is associated with weight gain. Reproductive dysfunction is reported in women and men with epilepsy treated with AEDs. In women, the most common symptoms are hyperandrogenism, menstrual disorders with ovulatory failure, polycystic ovary-appearing ovaries or polycystic ovary syndrome, and hyperinsulinemia. These symptoms may be secondary to epilepsy or to AED treatment, particularly with valproate. In men, effects on sperm quality and motility, delayed sexual development, and small testicular size have been described in association with AED treatment. Car-bamazepine reduces testosterone levels, whereas valproate increases androgen levels. Oxcarbazepine is not associated with changes in testosterone levels. Treatment with all of these agents can result in changes in sperm, including concentration, morphology, and motility. Enzyme-inducing AEDs are known to result in decreased thyroid hormones. Recent studies found reduced serum thyroid hormone concentrations in men and young girls treated with carbamazepine and oxcarbazepine. However, all patients were clini-cally euthyroid, and these changes were reversible after AED withdrawal. Persons with epilepsy treated with AEDs are at increased risk for fracture. Not only is this increased because of seizure activity, but also because of treatment with AEDs. AED treatment results in decreased bone mineral density, the most sensitive predictor of fracture and changes in biochemical indices of bone metabolism, including calcium, vitamin D, and markers of bone formation and resorption. Identifying each of these endocrine abnor-malities is important because it may be necessary and beneficial to change AED treat-ment. In addition, multiple therapies exist for the treatment of polycystic ovary syndrome, infertility, and decreased bone mineral density.
- 1 July 2005
- Published by Springer Nature in Current Treatment Options in Neurology
- Vol. 7 (4) , 273-280
Effects of treatment on endocrine function in patients with epilepsy
Antiepileptic drug (AED) treatment is associated with multiple short- and long-term side effects. Effects on endocrine function, including weight change, reproductive function, thyroid function, and bone health are examples of these side effects. Some AEDs affect weight, resulting in weight gain or loss. Levetiracetam and lamotrigine are weight-neu-tral agents, whereas valproate is associated with weight gain. Reproductive dysfunction is reported in women and men with epilepsy treated with AEDs. In women, the most common symptoms are hyperandrogenism, menstrual disorders with ovulatory failure, polycystic ovary-appearing ovaries or polycystic ovary syndrome, and hyperinsulinemia. These symptoms may be secondary to epilepsy or to AED treatment, particularly with valproate. In men, effects on sperm quality and motility, delayed sexual development, and small testicular size have been described in association with AED treatment. Car-bamazepine reduces testosterone levels, whereas valproate increases androgen levels. Oxcarbazepine is not associated with changes in testosterone levels. Treatment with all of these agents can result in changes in sperm, including concentration, morphology, and motility. Enzyme-inducing AEDs are known to result in decreased thyroid hormones. Recent studies found reduced serum thyroid hormone concentrations in men and young girls treated with carbamazepine and oxcarbazepine. However, all patients were clini-cally euthyroid, and these changes were reversible after AED withdrawal. Persons with epilepsy treated with AEDs are at increased risk for fracture. Not only is this increased because of seizure activity, but also because of treatment with AEDs. AED treatment results in decreased bone mineral density, the most sensitive predictor of fracture and changes in biochemical indices of bone metabolism, including calcium, vitamin D, and markers of bone formation and resorption. Identifying each of these endocrine abnor-malities is important because it may be necessary and beneficial to change AED treat-ment. In addition, multiple therapies exist for the treatment of polycystic ovary syndrome, infertility, and decreased bone mineral density.